Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - AT&S, Valneva, ams (04/08/2020)

09.08.2020

AT&S: AT&S, one of the globally leading manufacturers of high-end printed circuit boards and IC substrates, reported first quarter earnings. Although the COVID-19 pandemic changed day-to-day life in the market and in the company, AT&S was able to compensate for the effects on ongoing production at the locations and consequently for the economic impact. The company generated consolidated revenue of Euro 247.9 mn (PY: Euro 222.7 mn). EBITDA rose from Euro 34.9 mn to Euro 39.5 mn. The increase in earnings is primarily due to the higher consolidated revenue, taking into account that investments in research & development were intensified to prepare for future technology generations and to pursue the modularisation strategy. These expenditures make the company future-proof and significantly expand the earnings potential in the medium term. EBIT improved from Euro -0.6 mn to Euro 0.2 mn. AT&S expects a continued solid performance in the second quarter with revenue at the level of the previous year and an EBITDA margin in the target range of 20% to 25%.
AT&S: weekly performance: 6.37%

Valneva: Austrian/french vaccine developer Valneva’s total revenues in the first half of 2020 were Euro 47.9 mn compared to Euro 54.5 mn in the first half of 2019. Revenues in the first half of 2019 included negative revenue effects related to the termination of the Strategic Alliance Agreement (SAA) with GSK amounting to Euro 10.7 mn. Excluding the termination effect, total revenues would have amounted to €65.2 million in the first half of 2019. Product sales revenues in the first half of 2020 declined to Euro 40.9 mn compared to Euro 61.6 mn in the same period of 2019. On a CER basis26, product sales declined by 35% compared to the first half of 2019 with both commercial vaccines impacted by COVID-19 related consequences on the travel market. Research and development investments in the first half of 2020 continued to increase as planned, more than doubling to Euro 33 mn compared to Euro 14.1 mn in the first quarter of 2019. This was driven by investments into Valneva’s clinical stage vaccine candidates, notably Lyme and chikungunya. Valneva recorded an operating loss of Euro 21.9 mn in the first half of 2020 compared to Euro 1.7 mn in the first half of 2019. EBITDA loss in the first half of 2020 was Euro 17.2 mn compared to an EBITDA profit of Euro 2.4 mn in the first half of 2019. In the first half of 2020, Valneva generated a net loss amounting to Euro 25.6 mn compared to a net loss of Euro 2.4 mn in the first half of 2019. David Lawrence, Valneva’s Chief Financial Officer, commented, “The excellent progress across our business in all areas outweighs the adverse impact of the COVID-19 pandemic on the travel industry and our product sales revenues. The debt financing combined with the Pfizer partnership and the excellent progress with the UK Government collaboration puts the company in a very strong position.”
Valneva: weekly performance: 11.65%

ams: ams, a leading worldwide supplier of high performance sensor solutions, provides the latest sensor technology to midge medical, a German medical technology startup from Berlin, to develop a disruptive technology for science-backed rapid genetic and blood testing in a home and professional healthcare environment at a lower cost. A specifically developed sensor system allows spectrally resolved read out of amplified COVID-19 (SARS-CoV-2) virus particles, strengthening ams’ position in delivering high-quality consumer health diagnostics. The current COVID-19 (SARS-CoV-2) crisis has made it clear: experts suggest there is an urgent need for frequent high-quality testing of symptomatic and asymptomatic people to manage the current pandemic and future crises. The new test addresses the unmet need of frequent, affordable, rapid and mass testing during the pandemic. “The unique diagnostic vision of midge medical, in combination with ams’ highly-performant and sensitive spectral sensors, has resulted in a miniaturized readout at a fraction of the cost of currently available systems, enabling decentralized testing at home and in professional healthcare environments. The midge smartphone app delivers instant results that can be displayed on any authorized smartphone,” said Jennifer Zhao, Executive Vice President for Advanced Optical Sensors Division at ams.
AMS: weekly performance: 10.24%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (04/08/2020)


Partners









latest 21st Austria

21st Austria weekly - AT&S, Valneva, ams (04/08/2020)


09.08.2020


AT&S: AT&S, one of the globally leading manufacturers of high-end printed circuit boards and IC substrates, reported first quarter earnings. Although the COVID-19 pandemic changed day-to-day life in the market and in the company, AT&S was able to compensate for the effects on ongoing production at the locations and consequently for the economic impact. The company generated consolidated revenue of Euro 247.9 mn (PY: Euro 222.7 mn). EBITDA rose from Euro 34.9 mn to Euro 39.5 mn. The increase in earnings is primarily due to the higher consolidated revenue, taking into account that investments in research & development were intensified to prepare for future technology generations and to pursue the modularisation strategy. These expenditures make the company future-proof and significantly expand the earnings potential in the medium term. EBIT improved from Euro -0.6 mn to Euro 0.2 mn. AT&S expects a continued solid performance in the second quarter with revenue at the level of the previous year and an EBITDA margin in the target range of 20% to 25%.
AT&S: weekly performance: 6.37%

Valneva: Austrian/french vaccine developer Valneva’s total revenues in the first half of 2020 were Euro 47.9 mn compared to Euro 54.5 mn in the first half of 2019. Revenues in the first half of 2019 included negative revenue effects related to the termination of the Strategic Alliance Agreement (SAA) with GSK amounting to Euro 10.7 mn. Excluding the termination effect, total revenues would have amounted to €65.2 million in the first half of 2019. Product sales revenues in the first half of 2020 declined to Euro 40.9 mn compared to Euro 61.6 mn in the same period of 2019. On a CER basis26, product sales declined by 35% compared to the first half of 2019 with both commercial vaccines impacted by COVID-19 related consequences on the travel market. Research and development investments in the first half of 2020 continued to increase as planned, more than doubling to Euro 33 mn compared to Euro 14.1 mn in the first quarter of 2019. This was driven by investments into Valneva’s clinical stage vaccine candidates, notably Lyme and chikungunya. Valneva recorded an operating loss of Euro 21.9 mn in the first half of 2020 compared to Euro 1.7 mn in the first half of 2019. EBITDA loss in the first half of 2020 was Euro 17.2 mn compared to an EBITDA profit of Euro 2.4 mn in the first half of 2019. In the first half of 2020, Valneva generated a net loss amounting to Euro 25.6 mn compared to a net loss of Euro 2.4 mn in the first half of 2019. David Lawrence, Valneva’s Chief Financial Officer, commented, “The excellent progress across our business in all areas outweighs the adverse impact of the COVID-19 pandemic on the travel industry and our product sales revenues. The debt financing combined with the Pfizer partnership and the excellent progress with the UK Government collaboration puts the company in a very strong position.”
Valneva: weekly performance: 11.65%

ams: ams, a leading worldwide supplier of high performance sensor solutions, provides the latest sensor technology to midge medical, a German medical technology startup from Berlin, to develop a disruptive technology for science-backed rapid genetic and blood testing in a home and professional healthcare environment at a lower cost. A specifically developed sensor system allows spectrally resolved read out of amplified COVID-19 (SARS-CoV-2) virus particles, strengthening ams’ position in delivering high-quality consumer health diagnostics. The current COVID-19 (SARS-CoV-2) crisis has made it clear: experts suggest there is an urgent need for frequent high-quality testing of symptomatic and asymptomatic people to manage the current pandemic and future crises. The new test addresses the unmet need of frequent, affordable, rapid and mass testing during the pandemic. “The unique diagnostic vision of midge medical, in combination with ams’ highly-performant and sensitive spectral sensors, has resulted in a miniaturized readout at a fraction of the cost of currently available systems, enabling decentralized testing at home and in professional healthcare environments. The midge smartphone app delivers instant results that can be displayed on any authorized smartphone,” said Jennifer Zhao, Executive Vice President for Advanced Optical Sensors Division at ams.
AMS: weekly performance: 10.24%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (04/08/2020)




 

Bildnachweis

Aktien auf dem Radar:Mayr-Melnhof, Kapsch TrafficCom, Addiko Bank, FACC, Warimpex, UBM, voestalpine, Bawag, Zumtobel, Agrana, Cleen Energy, Erste Group, Immofinanz, OMV, Palfinger, Porr, Rosenbauer, Semperit, Stadlauer Malzfabrik AG, Pierer Mobility AG, LINDE.


Random Partner

Immofinanz
Die Immofinanz ist ein börsenotierter gewerblicher Immobilienkonzern, der seine Aktivitäten auf die Segmente Einzelhandel und Büro in sieben Kernmärkten in Europa (Österreich, Deutschland, Tschechien, Slowakei, Ungarn, Rumänien und Polen) fokussiert. Zum Kerngeschäft zählen die Bewirtschaftung und die Entwicklung von Immobilien.

>> Besuchen Sie 56 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten